Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Vipin Arora

Showing results (51-60 of 75) with videos related to

Pageof 8
Sort By:
The Pan African Medical Journal|December 1, 2022
Retrospective analysis of the role of retrobulbar amphotericin-B injection in the management of COVID-19 associated rhino-orbito-cerebral-mucormycosisRekha Yadav, Siddharth Madan, Jolly Rohatgi, et al.
Rheumatology (Oxford, England)|January 21, 2014
Recovery of clinical but not radiographic outcomes by the delayed addition of adalimumab to methotrexate-treated Japanese patients with early rheumatoid arthritis: 52-week results of the HOPEFUL-1 trialHisashi Yamanaka, Naoki Ishiguro, Tsutomu Takeuchi, et al.
Immunopharmacology and Immunotoxicology|December 19, 2024
Role of myeloid-derived suppressor and Th17/Treg cells in post-COVID-19 Rhino-Orbital mucormycosis casesPraveen Kumar Singh, Gargi Rai, Shukla Das, et al.
The British Journal of Dermatology|July 6, 2022
Efficacy and safety of mirikizumab in psoriasis: results from a 52-week, double-blind, placebo-controlled, randomized withdrawal, phase III trial (OASIS-1)Andrew Blauvelt, Alexa B Kimball, Matthias Augustin, et al.
The Journal of Pain|November 8, 2015
Disruption of Spinal Noradrenergic Activation Delays Recovery of Acute Incision-Induced Hypersensitivity and Increases Spinal Glial Activation in the RatVipin Arora, Carlos Eduardo Morado-Urbina, Carol A Aschenbrenner, et al.
Crohn'S & Colitis 360|May 25, 2026
The UCEIS and UC-100 score were responsive endoscopic and global indices in a phase 2 trial of ulcerative colitisSudheer K Vuyyuru, Simon Travis, Soushyant Kiarasi, et al.
Journal of Surgical Oncology|July 16, 2020
Discordance of COVID-19 guidelines for patients with cancer: A systematic reviewPankaj Kumar Garg, Pallvi Kaul, Deepti Choudhary, et al.
The Lancet. Rheumatology|January 22, 2024
Safety and efficacy of mirikizumab versus secukinumab and placebo in the treatment of moderate-to-severe plaque psoriasis (OASIS-2): a phase 3, multicentre, randomised, double-blind studyKim Papp, Richard B Warren, Lawrence Green, et al.
Lancet (London, England)|October 31, 2013
Adjustment of therapy in rheumatoid arthritis on the basis of achievement of stable low disease activity with adalimumab plus methotrexate or methotrexate alone: the randomised controlled OPTIMA trialJosef S Smolen, Paul Emery, Roy Fleischmann, et al.
Obesity Science & Practice|December 30, 2025
Relationships Between Metabolic and Bariatric Surgery and Adverse Kidney Outcomes: An Analysis of a Retrospective CohortKevin C Maki, Stephanie L Dickinson, Carol F Kirkpatrick, et al.
Pageof 8

Showing results (51-60 of 75) with videos related to

Sort By:
Pageof 8
The Pan African Medical Journal|December 1, 2022
Retrospective analysis of the role of retrobulbar amphotericin-B injection in the management of COVID-19 associated rhino-orbito-cerebral-mucormycosisRekha Yadav, Siddharth Madan, Jolly Rohatgi, et al.
Rheumatology (Oxford, England)|January 21, 2014
Recovery of clinical but not radiographic outcomes by the delayed addition of adalimumab to methotrexate-treated Japanese patients with early rheumatoid arthritis: 52-week results of the HOPEFUL-1 trialHisashi Yamanaka, Naoki Ishiguro, Tsutomu Takeuchi, et al.
Immunopharmacology and Immunotoxicology|December 19, 2024
Role of myeloid-derived suppressor and Th17/Treg cells in post-COVID-19 Rhino-Orbital mucormycosis casesPraveen Kumar Singh, Gargi Rai, Shukla Das, et al.
The British Journal of Dermatology|July 6, 2022
Efficacy and safety of mirikizumab in psoriasis: results from a 52-week, double-blind, placebo-controlled, randomized withdrawal, phase III trial (OASIS-1)Andrew Blauvelt, Alexa B Kimball, Matthias Augustin, et al.
The Journal of Pain|November 8, 2015
Disruption of Spinal Noradrenergic Activation Delays Recovery of Acute Incision-Induced Hypersensitivity and Increases Spinal Glial Activation in the RatVipin Arora, Carlos Eduardo Morado-Urbina, Carol A Aschenbrenner, et al.
Crohn'S & Colitis 360|May 25, 2026
The UCEIS and UC-100 score were responsive endoscopic and global indices in a phase 2 trial of ulcerative colitisSudheer K Vuyyuru, Simon Travis, Soushyant Kiarasi, et al.
Journal of Surgical Oncology|July 16, 2020
Discordance of COVID-19 guidelines for patients with cancer: A systematic reviewPankaj Kumar Garg, Pallvi Kaul, Deepti Choudhary, et al.
The Lancet. Rheumatology|January 22, 2024
Safety and efficacy of mirikizumab versus secukinumab and placebo in the treatment of moderate-to-severe plaque psoriasis (OASIS-2): a phase 3, multicentre, randomised, double-blind studyKim Papp, Richard B Warren, Lawrence Green, et al.
Lancet (London, England)|October 31, 2013
Adjustment of therapy in rheumatoid arthritis on the basis of achievement of stable low disease activity with adalimumab plus methotrexate or methotrexate alone: the randomised controlled OPTIMA trialJosef S Smolen, Paul Emery, Roy Fleischmann, et al.
Obesity Science & Practice|December 30, 2025
Relationships Between Metabolic and Bariatric Surgery and Adverse Kidney Outcomes: An Analysis of a Retrospective CohortKevin C Maki, Stephanie L Dickinson, Carol F Kirkpatrick, et al.
Pageof 8